Literature DB >> 18086564

Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.

Kenji Ishihara1, Hajime Kitamura, Kenji Hiraizumi, Motoko Kaneko, Aki Takahashi, Okpyo Zee, Toshio Seyama, Jangja Hong, Kazuo Ohuchi, Noriyasu Hirasawa.   

Abstract

The constitutively activated tyrosine kinase Fip1-like 1 (FIP1L1)-platelet-derived growth factor receptor alpha (PDGFRalpha) causes eosinophilic leukemia EoL-1 cells to proliferate. Recently, we demonstrated that histone deacetylase inhibitors suppressed this proliferation and induced the differentiation of EoL-1 cells into eosinophils in parallel with a decrease in the level of FIP1L1-PDGFRalpha. In this study, we analyzed the mechanism by which FIP1L1-PDGFRalpha induces the proliferation and whether the suppression of cell proliferation triggers the differentiation into eosinophils. The FIP1L1-PDGFRalpha inhibitor imatinib inhibited the proliferation of EoL-1 cells and decreased the level of the oncoprotein c-Myc as well as the phosphorylation of extracellular signal-regulated kinase and c-Jun N-terminal kinase (JNK). The proliferation of EoL-1 cells and expression of c-Myc were also inhibited by the MEK inhibitor U0126 and JNK inhibitor SP600125. The expression of the eosinophilic differentiation marker CCR3 was not induced by imatinib. These findings suggest that FIP1L1-PDGFRalpha induces the proliferation of EoL-1 cells through the induction of c-Myc expression via ERK and JNK signaling pathways, but is not involved in the inhibition of differentiation toward mature eosinophils.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086564     DOI: 10.1016/j.bbrc.2007.12.063

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.

Authors:  Daniel Wicklein; Nuno Ramos Leal; Johannes Salamon; Mohammed Thamer; Harald Herrmann; Peter Valent; Udo Schumacher; Sebastian Ullrich
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

2.  Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.

Authors:  Bin Li; Guangsen Zhang; Cui Li; Dan He; Xinying Li; Chunfang Zhang; Faqing Tang; Xiyun Deng; Jingchen Lu; Youhong Tang; Ruijuan Li; Zhuchu Chen; Chaojun Duan
Journal:  PLoS One       Date:  2012-04-16       Impact factor: 3.240

3.  The oncogenic FIP1L1-PDGFRα fusion protein displays skewed signaling properties compared to its wild-type PDGFRα counterpart.

Authors:  Serge Haan; Christelle Bahlawane; Jiali Wang; Petr V Nazarov; Arnaud Muller; René Eulenfeld; Claude Haan; Catherine Rolvering; Laurent Vallar; Venkata P Satagopam; Thomas Sauter; Monique Yvonne Wiesinger
Journal:  JAKSTAT       Date:  2015-07-17

4.  E- and p-selectins are essential for repopulation of chronic myelogenous and chronic eosinophilic leukemias in a scid mouse xenograft model.

Authors:  Daniel Wicklein; Anna Schmidt; Vera Labitzky; Sebastian Ullrich; Peter Valent; Udo Schumacher
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

5.  Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities.

Authors:  Makoto Ibata; Junko Iwasaki; Yoichiro Fujioka; Koji Nakagawa; Stephanie Darmanin; Masahiro Onozawa; Daigo Hashimoto; Yusuke Ohba; Shigetsugu Hatakeyama; Takanori Teshima; Takeshi Kondo
Journal:  Cancer Sci       Date:  2017-02       Impact factor: 6.716

6.  Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL.

Authors:  Bin Li; Guangsen Zhang; Cui Li; Ruijuan Li; Jingchen Lu; Zhengxi He; Quan Wang; Zhenzi Peng; Jun Wang; Yeping Dong; Chunfang Zhang; Jie Qiong Tan; Nacef Bahri; Yuexiang Wang; Chaojun Duan
Journal:  Oncotarget       Date:  2016-08-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.